Laurie B Schenkel

This inventor holds 26 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Amgen Inc., Ribon Therapeutics, Inc., Boehringer Ingelheim International Gmbh. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laurie B Schenkel. Retrieved from https://idiyas.com/inventor/laurie-b-schenkel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 17)

% Patents Active = 92.3

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 117(Granted Patents)

Location History:

Boston, MA (US) (2010 - 2017)
Somerville, MA (US) (2020 - 2024)
Cambridge, MA (US) (2022 - 2024)

Company Filing History:

Ribon Therapeutics, Inc.

patents

3 out of 1,562

Boehringer Ingelheim International Gmbh

patents

4. 2 out of 127

Teijin Pharma Limited

patents

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Benzimidazole Derivatives

Heterobicyclic Amides

PARP Inhibitors

Beta-Secretase Antagonists

PI3 Kinase Modulators

Quinazolinones

Pyridazinones

Aurora Kinase Modulators

Biaryl Acyl-Sulfonamide

Amino-Dihydrothiazine

Fused Multi-Cyclic Sulfone

Bridged Bicyclic Amino Thiazine

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492185 - Benzimidazole derivatives and their uses (2025-12-09),

2. 12398146 - Heterobicyclic amides as inhibitors of CD38 (2025-08-26),

3. 12371421 - Solid forms of a PARP7 inhibitor (2025-07-29),

4. 11987584 - Heterobicyclic amides as inhibitors of CD38 (2024-05-21),

5. 11958837 - Quinazolinones as PARP14 inhibitors (2024-04-16),

6. 11952377 - Quinolines and azaquinolines as inhibitors of CD38 (2024-04-09),

7. 11566020 - Pyridazinones as PARP7 inhibitors (2023-01-31),

8. 11535621 - Heterobicyclic amides as inhibitors of CD38 (2022-12-27),

9. 11332459 - Benzimidazole derivatives and their uses (2022-05-17),

10. 11293927 - Screening methods for PARP modulators (2022-04-05),

11. 11014913 - Pyridazinones as PARP7 inhibitors (2021-05-25),

12. 11008308 - Quinazolinones as PARP14 inhibitors (2021-05-18),

13. 10870641 - Pyridazinones as PARP7 inhibitors (2020-12-22),

14. 10562891 - Quinazolinones as PARP14 inhibitors (2020-02-18),

15. 10550105 - Pyridazinones as PARP7 inhibitors (2020-02-04),

Title: Inventor Spotlight: Laurie B Schenkel

Introduction:

Laurie B Schenkel, a brilliant inventor based in Cambridge, MA (US), has made significant contributions to the fields of cancer treatment and inflammatory disease management. With an impressive portfolio of 22 patents, Laurie is recognized for her innovative approach to developing compounds that inhibit key enzymes involved in disease progression.

Latest Patents:

1. Quinazolinones as PARP14 inhibitors - Laurie's groundbreaking invention involves quinazolinones and related compounds that act as potent inhibitors of PARP14. These compounds demonstrate utility in the treatment of cancer and inflammatory diseases, showcasing Laurie's commitment to advancing therapeutic solutions.

2. Quinolines and azaquinolines as inhibitors of CD38 - In another cutting-edge invention, Laurie introduces bicyclic heterocycle compounds that serve as inhibitors of CD38. These compounds hold promise in addressing disease mechanisms, highlighting Laurie's expertise in drug development.

Career Highlights:

Laurie B Schenkel's remarkable career includes notable tenures at renowned companies such as Amgen Inc. and Ribon Therapeutics, Inc. Her innovative mindset and dedication to scientific advancement have driven breakthroughs in the pharmaceutical industry, setting her apart as a visionary inventor.

Collaborations:

Throughout her career, Laurie has collaborated with esteemed professionals in the field, including coworkers Melissa Marie Vasbinder and Kevin Wayne Kuntz. These collaborations have fostered a dynamic exchange of ideas, leading to impactful innovations that have the potential to transform healthcare practices.

Conclusion:

In conclusion, Laurie B Schenkel stands as a trailblazing inventor with a passion for developing novel therapeutic solutions. Her exceptional patent portfolio and collaborative spirit reflect a commitment to pushing boundaries and shaping the future of medicine. Laurie's contributions continue to inspire and pave the way for groundbreaking advancements in disease treatment and management.

Profile summary based on public USPTO records.